08:15 AM EST, 03/07/2025 (MT Newswires) -- Plus Therapeutics ( PSTV ) said Friday that its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.

The clinical-stage company said that the study showed no dose-limiting toxicity, and that the majority of adverse events were unrelated to the treatment.

Plus Therapeutics ( PSTV ) said that, based on these results, it is currently enrolling patients in a mid-stage trial at medical centers.

Shares of the company climbed as much as 40% in recent premarket activity on Friday.